Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus MONISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus MONISTAT.
AMPHOTEC vs MONISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Miconazole, the active ingredient in MONISTAT, inhibits fungal CYP51 (lanosterol 14-alpha-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity, leading to cell death.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Intravaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 2% cream 5 g intravaginally at bedtime for 7 days. Topical: Apply 2% cream twice daily for 2-4 weeks.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Approximately 90-120 minutes; supports twice-daily local dosing.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Primarily fecal (approximately 90%) as unchanged drug; less than 2% renal elimination.
Category C
Category C
Antifungal
Antifungal